Sfoglia per AUTORE
SORIA JC
Collezione AOU San Luigi di Orbassano
Items : 3
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2014 Nov;25(11):2156-2162. doi: 10.1093/annonc/mdu384. Epub 2014 Aug 19.
2014
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC;
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. in Clinical lung cancer / Clin Lung Cancer. 2012 Sep;13(5):391-5. doi: 10.1016/j.cllc.2012.01.003. Epub 2012 Mar 21.
2012
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB;
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.
2012
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC;